Xintiandi (301277.SZ) announced first-half results, net profit of 607.673 million yuan to mother, a year-on-year decrease of 22.13%

According to the Zhitong Finance App, Xintiandi (301277.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 397 million yuan, an increase of 10.64% over the previous year. Achieved net profit of 607.673 million yuan attributable to shareholders of listed companies, a year-on-year decrease of 22.13%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 54.716,600 yuan, a year-on-year decrease of 23.78%.

During the reporting period, the company's production and operation were normal. The main product, L-para-hydroxyphenylglycine, had revenue of 304 million yuan, an increase of 1.54% over the same period last year. The company has been deeply involved in the L-hydroxyphenylglycine industry for many years, continuously optimized process technology, and independently developed and formed core technologies such as L-parahydroxyphenylglycine preparation, by-product control and green production, and has core competitiveness in cost and production control. Facing a complex and changing market environment, the company adheres to “independent innovation+external cooperation” two-wheel drive, continuously optimizes and upgrades production processes, and actively promotes automation and intelligent transformation of the production process. Through technological iteration and operational efficiency improvement, the company further enhances product profitability and resilience to risks.